Shuguang Zhang is an American scientist who studies living things. He works at a lab at MIT Media Lab called the Laboratory for Molecular Architecture. His research involves creating and studying biological molecules, especially proteins and peptides. He has written more than 210 scientific papers. These papers have been cited over 42,900 times, and his h-index is 98. According to a database that tracks scientific citations, he is ranked 18th globally in Biomedical Engineering. He is a co-founder and board member of the Molecular Frontiers Foundation. This group holds yearly symposiums in Sweden and other countries. Winners of these events receive the Molecular Frontiers Inquiry Prize.

Early life and education

Shuguang Zhang earned a Bachelor of Science degree in biochemistry from Sichuan University in 1980. He later received a Doctor of Philosophy degree in Biochemistry and Molecular Biology from the University of California at Santa Barbara in 1988, with the guidance of Eduardo Orias. In the same year, he began working at MIT with Alexander Rich.

Career and scientific work

In 1990, Shuguang Zhang accidentally discovered a self-assembling peptide in a yeast protein called Zuotin. This discovery created a new area of science called peptide nanobiotechnology and led to the creation of many self-assembling peptides used in various ways, such as making hydrogels for materials science, growing 3D tissues for medical research, developing medicines, controlling the release of molecules over time, and treating wounds and injuries in clinical and surgical settings. Zhang helped start a company named 3DMatrix that uses self-assembling peptide materials in human medical treatments for conditions like diabetic ulcers, bedsores (pressure ulcers), and faster wound healing, as well as in surgeries. Many self-assembling peptide products have been approved by the U.S. Food and Drug Administration (FDA), the European Medicine Agency (EMA), Japan’s medical authority, and Chengdu’s medical approval agency in China.

Less well-known, Zhang also invented the QTY Code, a method to change insoluble peptide sequences into water-soluble ones, which helps scientists study proteins without altering their natural shape or function. In 2011, Zhang began designing membrane proteins because about 26% of genes in living organisms code for membrane proteins, which are essential for communication between the inside and outside of cells. He created a simple method using three amino acids—Glutamine (Q), Threonine (T), and Tyrosine (Y)—to replace hydrophobic amino acids like Leucine (L), Valine (V), Isoleucine (I), and Phenylalanine (F) in the 7 transmembrane alpha-helices of G protein-coupled receptors (GPCRs). This change makes membrane proteins, including GPCRs, water-soluble. Studies show that even though up to 56% of the transmembrane alpha-helices are altered, the water-soluble QTY versions still keep their structure and function, such as their ability to bind to other molecules. This method is a useful tool for creating water-soluble versions of proteins that are otherwise hard to study or work with, including amyloids.

The QTY Code is a major breakthrough in protein engineering that allows hydrophobic membrane proteins to be converted into water-soluble, functional versions. It represents a way of thinking about proteins as if their properties, such as whether they prefer water or oil, can be changed like a code. This approach suggests that characteristics of living things are not fixed but can be adjusted through scientific methods.

Fellowships and awards

• Received a postdoctoral fellowship from the American Cancer Society
• Served as an investigator at MIT through the Whitaker Foundation
• Awarded a Guggenheim Fellowship in 2006
• Had an academic sabbatical at the University of Cambridge
• Received the Wilhelm Exner Medal from Austria in 2006
• Elected to the Austrian Academy of Sciences in 2010
• Elected to the American Institute of Medical and Biological Engineering in 2011
• Elected to the US National Academy of Inventors in 2013
• Received the Emil Thomas Kaiser Award from the Protein Society in 2020
• Elected to the European Academy of Science and Arts in 2021
• Elected as an honorary fellow of the Erwin Schrödinger Society at the Austrian Academy of Sciences in 2021
• Received the Eva and George Klein Medal from the Karolinska Institute in Stockholm, Sweden, in 2024